Skip to content

Ketamine: all studies

Page 57 of 449: studies 561 to 570 of 4,489, newest first. Back to the ketamine overview

Research

Ketamine and its Regulatory Implications: A Review

Journal of Medical Regulation December 1, 2025 Amol Soin, Y.c. Janardhan Reddy, Kris Ferguson et al.

ABSTRACT: Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has been approved for use as a clinical and veterinary anesthetic since 1970. Although esketamine, a specific molecular form of ketamine, is FDA-approved for the management of treatment-resistant depression, regular ketamine is often used off-label at subanesthetic doses to treat depression as well as other...

Effect of Ketamine Supplementation in Axillary Plexus Blockade: A Comparative Study.

Cureus December 1, 2025 Demetra Solomos, Aggeliki Bairaktari, Theodoros Xanthos et al.

Introduction Axillary brachial plexus block is a widely used regional anesthesia technique for below-elbow surgeries. The use of adjuvant medications can influence block characteristics and postoperative pain experience. This randomized, prospective, single-blind comparative study aimed to evaluate whether ketamine, administered intravenously or regionally with ropivacaine, affects...

Ketamine-Induced Cholangiopathy With Concomitant Hemorrhagic Cystitis: An Emerging and Underrecognized Cause of Cholestasis.

Cureus December 1, 2025 Kamran Nazir, Waqas Ahmed, Salman Rafi et al.

Ketamine-induced cholangiopathy (KIC) is a rare but increasingly recognized manifestation of chronic ketamine toxicity, often accompanied by urinary tract injury such as hemorrhagic cystitis. We report the case of a 55-year-old female with recurrent hemorrhagic cystitis and a long-standing history of intermittent recreational ketamine use who presented with asymptomatic cholestatic liver enzyme...

DOI: 10.7759/cureus.99972 (opens in new tab) Full text (opens in new tab) Biliary stricture Hepatobiliary complication Ketamine-induced cholangiopathy Ketamine-induced cystitis +1

Ketamine infusion therapy for treatment-resistant major depressive disorder and suicidal ideation: Nursing care and considerations.

Nursing December 1, 2025 Rebecca Ann Ivory, Kathryn M. Pate, Brentyn M Jones et al.

Major depressive disorder (MDD) affects approximately 332 million people worldwide. Among those diagnosed with MDD, approximately 53% receive pharmacologic treatment, such as ketamine. Nurses must be knowledgeable about ketamine and other emerging, effective behavioral health therapies used to treat chronically depressed mood and acute suicidal ideation. This article outlines the best nursing...

The Ketamine Trial for Acute Suicidality (KETA): Study Protocol of a Double-Blind Randomized Placebo-Controlled Superiority Trial on Intranasal Racemic Ketamine Compared to the Active Placebo Intranasal Midazolam as Treatment for Acute Suicidality.

International Journal of Methods in Psychiatric Research December 1, 2025 Jurriaan F M Strous, Gijs H J Roelandt, Jens H van Dalfsen et al. 1 citation

Suicidality is a transdiagnostic entity in patients with and without psychiatric disorders. Ketamine is a novel treatment for treatment-resistant depression with favorable effects on related suicidality in this population. Little is known about the effects of ketamine on suicidality as a distinct phenomenon. To assess whether a dose of 75 mg intranasal (IN) ketamine reduces acute suicidality...

DOI: 10.1002/mpr.70044 (opens in new tab) Full text (opens in new tab) Randomized controlled trial Ketamine for suicidality Rapid intervention

S100B+ Astrocytes Are Altered in the Mouse Brain Upon Ketamine Challenge: Implications for the Symptoms of Schizophrenia.

Journal of Biochemical and Molecular Toxicology December 1, 2025 Nimmi Varghese, Aadithye Ravikumar Nair, Parayil Sobha Anumol et al.

Schizophrenia is a complex neuropsychiatric disorder characterized by positive, negative and cognitive symptoms. The pathophysiology of schizophrenia is largely unknown, but it is understood that this mental disorder is a manifestation of genetic, environmental and biological factors. Herein, we focus on S100B, a family of calcium binding cytosolic proteins that play a profound role in glial...

DOI: 10.1002/jbt.70613 (opens in new tab) Full text (opens in new tab) Cerebral cortex Hippocampus Olfactory Schizophrenia schizophrenia model +15

Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review

Journal of Education, Health and Sport November 29, 2025 Natalia Dudziak, Zuzanna Drozd, Bartosz Niemiec et al.

Background. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with acute suicidal ideation need immediate intervention, yet conventional antidepressants require weeks to work. Esketamine offers rapid symptom reduction through NMDA receptor antagonism. Aim. To systematically review current evidence on efficacy and...

Ketamine attenuates anxiety-like behavior and oxidative imbalance in the maternal immune activation model: emphasis on the cerebellum.

Psychopharmacology November 28, 2025 Elifrances Galdino de Oliveira, Mayara Victória De Souza Barbosa, Diógenes Afonso De Lima et al.

Relevant to the study of neurodevelopmental disorders, maternal immune activation (MIA) models reproduce the high incidence of anxiety disorders and molecular alterations in the cerebellum reported in patients with schizophrenia and autism. In parallel, ketamine, a fast-acting antidepressant, has shown beneficial effects in psychiatric disorders with immune-related components. To investigate...

A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model

Scientific Reports November 26, 2025 Małgorzata Domżalska, Joanna Kwiatkowska, Iwona Cichoń et al. 2 citations

Depression is a debilitating mental disorder affecting millions worldwide, yet current pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), often exhibit delayed onset and limited efficacy. The chronic social defeat (CSD) stress model in mice is a well-established preclinical paradigm for inducing depression-like behaviors and evaluating antidepressants...

Repeated ketamine exposure induces psychotic-like behaviors in mice via DRD1-mediated phosphorylation of p-Thr34 DARPP-32 and p-Ser10 histone H3

Cell Biology and Toxicology November 25, 2025 Peng Lv, Jiayu Zhang, Jia-Yi Wei et al.

Psychotic disorders frequently result from repeated ketamine exposure, yet the underlying mechanisms remain elusive. We propose that repeated exposure to ketamine may induce psychotic-like behaviors via DRD1-mediated nuclear signaling pathways. Our investigation focused on phosphorylated DARPP-32 at Thr34, Thr75, and Ser97, alongside transcriptome profiling in both cell and mouse models. We...